Evaluation of the correlation between porphyrin accumulation in cancer cells and functional positions for application as a drug carrier

Porphyrin derivatives accumulate selectively in cancer cells and are can be used as carriers of drugs. Until now, the substituents that bind to porphyrins (mainly at the meso-position) have been actively investigated, but the effect of the functional porphyrin positions (beta-, meso-position) on tumor accumulation has not been investigated. Therefore, we investigated the correlation between the functional position of substituents and the accumulation of porphyrins in cancer cells using cancer cells. We found that the meso-derivative showed higher accumulation in cancer cells than the beta -derivative, and porphyrins with less bulky substituent actively accumulate in cancer cells. When evaluating the intracellular distribution of porphyrin, we found that porphyrin was internalized by endocytosis and direct membrane permeation. As factors involved in these two permeation mechanisms, we evaluated the affinity between porphyrin-protein (endocytosis) and the permeability to the phospholipid bilayer membrane (direct membrane permeation). We found that the binding position of porphyrin affects the factors involved in the transmembrane permeation mechanisms and impacts the accumulation in cancer cells.

Automated summary

This study revealed that the functional positions of porphyrins have a significant impact on their accumulation in cancer cells. Meso-derivatives accumulate more in cancer cells than beta-derivatives, and porphyrins with less bulky substituents tend to actively accumulate in cancer cells. Additionally, the binding position of porphyrin affects factors involved in transmembrane permeation mechanisms, ultimately impacting accumulation in cancer cells.